Compare Schwab US Dividend Equity ETF (SCHD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Dividend Equity ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Schwab US Dividend Equity ETF trades at $32.81, while State Street SPDR S&P Biotech ETF trades at $154.4. Which is the better fit depends on your goals.
| SCHD | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $33.04 | $164.28 |
52-Week Low | $26.38 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHD trades at $32.75, down 0.49% on the day, with strong technical momentum showing 17 bullish signals versus no sell signals. The ETF has delivered approximately 20% returns year-to-date in 2026, outperforming both the S&P 500 and Nasdaq-100. Recent news highlights SCHD's defensive sector allocation and dividend sustainability as key strengths amid market volatility.
The outlook remains positive given SCHD's focus on quality dividend stocks with 10+ years of payment history. Key opportunities include defensive positioning against AI bubble risks and consistent income generation. Risks include potential underperformance during growth stock rallies and sector concentration in healthcare and consumer defensive sectors.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
